

Quest Diagnostics

PATIENT INFORMATION

REPORT STATUS: FINAL

SPECIMEN INFORMATION

ORDERING PHYSICIAN

SPECIMEN:
REQUISITION:
LAB REF NO:

DOB:
AGE:
GENDER:
FASTING:

CLIENT INFORMATION

DirectLabs
4040 Florida St.
Ste 101
Mandeville, LA 70448

COLLECTED:
RECEIVED:
REPORTED:

Clinical Info:

Test Name	Result	Flag	Reference Range	Lab
FASTING: YES				
CARDIO IQ(R) ADVANCED LIPID PANEL AND INFLAMMATION PANEL				
CHOLESTEROL, TOTAL	198		125-200 mg/dL	01

Adult Reference Ranges for Cholesterol, Total:**

> or = 20 Years: 125-200 mg/dL

- <200 (Desirable)
- 200-239 (Borderline)
- >=240 (Higher Risk)

References:

** An executive summary of the NCEP guidelines, the "Third Report of the NCEP Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults." Journal of the American Medical Association. May 16, 2001.

HDL CHOLESTEROL	86		> OR = 40 mg/dL	01
TRIGLYCERIDES	69		mg/dL	01

Adult Reference Ranges for Triglycerides**:

- <150 mg/dL (Normal)
- 150-199 mg/dL (Borderline High)
- 200-499 mg/dL (High)
- >=500 mg/dL (Very High)

References:

** An executive summary of the NCEP guidelines, the "Third Report of the NCEP Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults." Journal of the American Medical Association. May 16, 2001.

LDL-CHOLESTEROL	98		mg/dL	01
-----------------	----	--	-------	----

Reference Range:

- <130 (DESIRABLE)
- 130-159 (BORDERLINE)
- >=160 (HIGH)

Desirable range <100 mg/dL for patients with CHD or diabetes and <70 mg/dL for diabetic patients with known heart disease.

CHOL/HDLRATIO	2.3		< OR = 5.0 calc	01
NON HDL CHOLESTEROL	112		mg/dL	01

Target for non-HDL cholesterol is 30 mg/dL higher than LDL cholesterol target

LDL PARTICLE NUMBER	1537		1016-2185 nmol/L	01
---------------------	------	--	------------------	----

	Risk: Optimal <1260; Moderate 1260-1538; High >1538		
LDL SMALL	211	123-441 nmol/L	01
	Risk: Optimal <162; Moderate 162-217; High >217		
LDL MEDIUM	263	167-465 nmol/L	01
	Risk: Optimal <201; Moderate 201-271; High >271		
HDL LARGE	7807	4334-10815 nmol/L	01
	Risk: Optimal >9386; Moderate 9386-6996; High <6996		
LDL PATTERN	A	A Pattern	01
	Risk: Optimal Pattern A; High Pattern B		
LDL PEAK SIZE	226.7	> OR = 218.2 Angstrom	01

Risk: Optimal >222.5; Moderate 222.5-218.2; High <218.2

Adult cardiovascular event risk category cut points (optimal, moderate, high) are based on adult U.S. reference population. Association between lipoprotein subfractions and cardiovascular events is based on Musunuru et al. ATVB. 2009;29:1975.

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Nichols Institute San Juan Capistrano. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

APOLIPOPROTEIN B	78	52-109 mg/dL	01
	Risk: Optimal < 80 mg/dL; Moderate 80-119 mg/dL; High > or = 120 mg/dL Cardiovascular event risk category cut points (optimal, moderate, high) are based on National Lipid Association recommendations - Davidson et al. J Clin Lipidol. 2011;5:338		

LIPOPROTEIN (a)	78	HIGH <75 nmol/L	01
	Risk: Optimal < 75 nmol/L; Moderate 75-125 nmol/L; High > 125 nmol/L Cardiovascular event risk category cut points (optimal, moderate, high) are based on Marcovina et al. Clin Chem. 2003;49:1785 and Nordestgaard et al. European Heart J. 2010;31:2844 (results of meta-analysis and expert panel recommendations).		

HS CRP	<0.2	mg/L	01
--------	------	------	----

For Ages > 17 Years:

hs-CRP mg/L	Risk According to AHA/CDC Guidelines
-----	-----
<1.0	Lower Relative Cardiovascular Risk.
1.0-3.0	Average Relative Cardiovascular Risk
3.1-10.0	Higher Relative Cardiovascular Risk.
	Consider retesting in 1 to 2 weeks to exclude a benign transient elevation in the baseline CRP value secondary to infection or inflammation.
>10.0	Persistent elevations upon retesting, may be associated with infection and inflammation.

LP PLA2 ACTIVITY	87	70-153 nmol/min/mL	01
------------------	----	--------------------	----

Risk: Optimal <=123 nmol/min/mL; High >123 nmol/min/mL.

The Lp-PLA2 Activity test measures the function of the Lp-PLA2 enzyme versus the concentration (mass) of the enzyme. As a result of the differences in reporting ranges, patient test results from the Lp-PLA2 (PLAC(R)) mass assay cannot be used for direct comparison to the results of the Cardio IQ Lp-PLA2 Activity assay, but for your reference the risk cut points for the discontinued Lp-PLA2 Mass test were Optimal <200 ng/mL; Moderate 200-235 ng/mL; High >235 ng/mL.

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Nichols Institute San Juan Capistrano. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

Performing Laboratory Information:

01: Quest Diagnostics/Nichols SJC-San Juan Capistrano,, 33608 Ortega Hwy, San Juan Capistrano CA, phone:
Medical Director: MD, PhD Jon Nakamoto